Aresus enters into a research collaboration agreement for Sinecatechins (Veregen®) with the European Skin Cancer Foundation and the Charité Berlin

Aresus enters into a research collaboration agreement for Sinecatechins (Veregen®) with the European Skin Cancer Foundation and the Charité Berlin 25 May 2020 Strausberg – Aresus Pharma GmbH announces today the closure of a research collaboration agreement with the European Skin Cancer Foundation and Charité, Berlin on the characterization of the antiproliferative and proapoptotic effects […]

Read More »

Two new products for Dr. Pfleger Arzneimittel

The Bamberg-based, medium-sized enterprise is further expanding its product range with the two products VEREGEN® and TAMSUBLOCK® DUO. Bamberg 12 May 2020 Following the conclusion of an exclusive sales agreement with Aresus Pharma GmbH, Dr. Pfleger Arzneimittel GmbH is to take over the marketing of VEREGEN® 10% ointment. “VEREGEN® 10% ointment complements our existing product […]

Read More »

The sale of Veregen

Read Medigene‘s press release on the sale of Veregen® here. Aresus acquires the Veregen® business as well as the complete inventory of the active pharmaceutical ingredient (API) and intends to invest in the expansion of Veregen® into additional indications and markets… Press Release

Read More »